Dilated cardiomyopathy future or investigational therapies: Difference between revisions
No edit summary |
|||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
New promising treatments for dilated cardiomyopathy include -among others- stem cell-based treatments, cholesterol-lowering drugs in combination with angiotensin receptor blockers, and protein A immunoadsorption. | |||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
There are several new therapies, currently under investigation for dilated cardiomyopathy. The most promising of these therapies include: | |||
* Stem cell-based treatments: Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) | |||
* Cholesterol lowering drugs as Simvastatin or Rosuvaststin, alone or in combination with angiotensin receptor blockers as valsartan or olmesartan. | |||
* Protein A Immunoadsorption: an extracorporeal technique used for the removal of IgG antibodies and molecules. | |||
* Other drugs under investigation include Qiliqiangxin, Ranolazine, and Benazepril. <br /> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 01:49, 13 December 2019
Dilated cardiomyopathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dilated cardiomyopathy future or investigational therapies On the Web |
American Roentgen Ray Society Images of Dilated cardiomyopathy future or investigational therapies |
FDA on Dilated cardiomyopathy future or investigational therapies |
CDC on Dilated cardiomyopathy future or investigational therapies |
Dilated cardiomyopathy future or investigational therapies in the news |
Blogs on Dilated cardiomyopathy future or investigational therapies |
Risk calculators and risk factors for Dilated cardiomyopathy future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]
Overview
New promising treatments for dilated cardiomyopathy include -among others- stem cell-based treatments, cholesterol-lowering drugs in combination with angiotensin receptor blockers, and protein A immunoadsorption.
Future or Investigational Therapies
There are several new therapies, currently under investigation for dilated cardiomyopathy. The most promising of these therapies include:
- Stem cell-based treatments: Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC])
- Cholesterol lowering drugs as Simvastatin or Rosuvaststin, alone or in combination with angiotensin receptor blockers as valsartan or olmesartan.
- Protein A Immunoadsorption: an extracorporeal technique used for the removal of IgG antibodies and molecules.
- Other drugs under investigation include Qiliqiangxin, Ranolazine, and Benazepril.